Dentico P, Volpe A, Buongiorno R, Maracchione N, Carbone M, Manno C, Proscia F
Istituto Policattedra Clinica Medica e Malattie Infettive, Università di Bari, Italy.
Nephron. 1992;61(3):324-5. doi: 10.1159/000186924.
The 7-year follow-up with plasma-derived and 2-year follow-up with r-DNA vaccines have indicated the safety, immunogenicity and persistence of a vaccine-induced antibody response in hemodialysis patients. The results of our study indicate that these subjects have a lower and often inadequate immunogenic response to the HB vaccine and that the r-DNA vaccine gives a better seroconversion rate than the plasma-derived vaccines.
对血浆源性疫苗的7年随访以及对重组DNA疫苗的2年随访表明，疫苗诱导的抗体反应在血液透析患者中具有安全性、免疫原性和持久性。我们的研究结果表明，这些受试者对乙肝疫苗的免疫原性反应较低且往往不足，并且重组DNA疫苗的血清转化率高于血浆源性疫苗。
